Commodore Capital LP Nurix Therapeutics, Inc. Transaction History
Commodore Capital LP
- $1.02 Billion
- Q1 2025
A detailed history of Commodore Capital LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Commodore Capital LP holds 3,978,907 shares of NRIX stock, worth $39.9 Million. This represents 4.63% of its overall portfolio holdings.
Number of Shares
3,978,907
Previous 3,000,000
32.63%
Holding current value
$39.9 Million
Previous $56.5 Million
16.37%
% of portfolio
4.63%
Previous 5.66%
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$68.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$55.2 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$44.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$40.7 Million5.06% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$39 Million0.55% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $473M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...